What is CV Sciences?
Headquartered in San Diego, California, CV Sciences operates at the intersection of pharmaceutical innovation and consumer health. The company maintains a bifurcated structure: a Pharmaceutical Division dedicated to the rigorous development of FDA-approved, synthetically formulated cannabidiol medicines, and a Consumer Products Division focused on high-quality botanical wellness solutions. Since its inception in 2010, the organization has navigated the complex regulatory environment surrounding cannabinoids, positioning itself as a key player in both clinical research and the broader health-conscious retail market. Their strategic focus remains on bridging the gap between traditional botanical applications and evidence-based medical science.
How much funding has CV Sciences raised?
CV Sciences has raised a total of $15.1M across 4 funding rounds:
Debt
$2M
Debt
$2M
Other Financing Round
$10M
Debt
$1.1M
Debt (2016): $2M, investors not publicly disclosed
Debt (2020): $2M led by PPP
Other Financing Round (2020): $10M supported by Tumim Stone Capital
Debt (2021): $1.1M, investors not publicly disclosed
Key Investors in CV Sciences
Tumim Stone Capital
An investment firm focused on providing strategic capital and financial solutions to growth-oriented companies across various sectors.
PPP
Public-Private Partnership
Undisclosed Investor
An undisclosed institutional backer participating in the latest financing round to support long-term strategic initiatives.
What's next for CV Sciences?
With the recent infusion of capital, CV Sciences is poised to accelerate its clinical development pipeline, specifically targeting regulatory milestones for its pharmaceutical candidates. The strategic allocation of these funds will likely prioritize the expansion of its consumer product distribution channels and the enhancement of its research infrastructure. As the company moves forward, the focus will shift toward scaling its manufacturing capabilities and deepening its intellectual property portfolio. Investors are closely monitoring the firm's ability to translate these financial resources into tangible clinical outcomes and increased market share, as the company seeks to solidify its leadership in the evolving cannabinoid industry.
See full CV Sciences company page
